

AMENDED PAGE ONE OF THE SPECIFICATION

USE OF THE NEUROTOXIC COMPONENT OF A BOTULINUM TOXIN FOR
TREATING A SPASTIC MUSCLE VARIOUS DISORDERS AND CONDITIONS
AND ASSOCIATED PAIN

CROSS-REFERENCE

This application is a continuation in part of application serial number 08/627,118, filed April 3, 1996, now U.S. patent 6,974,578, which is a continuation of application serial number 08/173,996, filed December 28, 1993, now abandoned.

FIELD OF THE INVENTION

The present invention provides novel methods for treating various disorders and conditions, with Botulinum toxins. Importantly, the present invention provides methods useful in relieving pain related to muscle activity or contracture and therefore is of advantage in the treatment of, for example, muscle spasm such as Temporomandibular Joint Disease, low back pain, myofascial pain, pain related to spasticity and dystonia, as well as sports injuries, and pain related to contractures in arthritis.

BACKGROUND OF THE INVENTION

Heretofore, Botulinum toxins, in particular Botulinum toxin type A, has been used in the treatment of a number of neuromuscular disorders and conditions involving muscular spasm; for example, strabismus, blepharospasm, spasmodic torticollis (cervical dystonia), oromandibular dystonia and spasmodic dysphonia (laryngeal dystonia). The toxin binds rapidly and strongly to presynaptic cholinergic nerve terminals and inhibits the exocytosis of